Asco 2025 · Posters · Cáncer Gastrointestinal · Elena Elez, MD, PhD Volver

Quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) analysis of pembrolizumab (pembro) versus chemotherapy (chemo) in microsatellite instability–high (MSI-H)/mismatch repair–deficient (dMMR) metastatic colorectal cancer (mCRC) in the KEYNOTE-177 trial.

Abstract: 3631
Poster Bd #: 300
Descargar Poster

Elena Elez, MD, PhD

Vall d´ Hebron University. Hospital and Institute of Oncology (VHIO)

Una iniciativa científica de: Eco Logo
Clover sgm Logo
Con el patrocinio de: Regeneron Logo